Neuroendocrine tumors (NETs) are complex cancers that can originate in various organs, including the ovaries. While primary ovarian NETs (PON) are uncommon, distinguishing them from
As the Director of Research at the Neuroendocrine Tumor Research Foundation (NETRF), I’ve dedicated my career to advancing science that gives patients and families more
The U.S. Food and Drug Administration (FDA) has approved cabozantinib for the treatment of previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic neuroendocrine tumors
Chimeric Therapeutics is reporting early signs of efficacy in the world’s first clinical trial of CAR T cell therapy for neuroendocrine cancer. The first NET
Neuroendocrine cancer researchers from around the world gathered in Krakow, Poland for the 22nd Annual ENETS Conference in early March. The European Neuroendocrine Tumor Society
Model systems—whether in vitro (cell lines), ex vivo (organoids), or in vivo (animal models)—are essential for understanding neuroendocrine cancer biology and testing new therapies. However,
The investigational therapy ITM-11 has shown promising results in the Phase 3 COMPETE trial for patients with inoperable, progressive Grade 1 and Grade 2 gastroenteropancreatic
The U.S. Food and Drug Administration (FDA) has granted priority review to Merck’s application for WELIREG® (belzutifan) as a treatment for adult and pediatric patients
In 2021, NETRF funded Paul Schaffer, PhD, of the University of British Columbia, for a pilot project entitled “Preclinical Toxicity and Therapy Study of 225Ac-crown-TATE.”
The Neuroendocrine Tumor Research Foundation (NETRF) has announced our newest neuroendocrine cancer research grant recipients. The ten investigators receiving awards are studying the most promising
